Display options
Cite
Tilak M, Alural B, Wismer SE, et al. Adaptor Protein ShcD/. Mol Cancer Res. 2021;19(5):757-770doi: 10.1158/1541-7786.MCR-20-0188.
Tilak, M., Alural, B., Wismer, S. E., Brasher, M. I., New, L. A., Sheridan, S. D., Perlis, R. H., Coppolino, M. G., Lalonde, J., & Jones, N. (2021). Adaptor Protein ShcD/. Molecular cancer research : MCR, 19(5), 757-770. https://doi.org/10.1158/1541-7786.MCR-20-0188
Tilak, Manali, et al. "Adaptor Protein ShcD/." Molecular cancer research : MCR vol. 19,5 (2021): 757-770. doi: https://doi.org/10.1158/1541-7786.MCR-20-0188
Tilak M, Alural B, Wismer SE, Brasher MI, New LA, Sheridan SD, Perlis RH, Coppolino MG, Lalonde J, Jones N. Adaptor Protein ShcD/. Mol Cancer Res. 2021 May;19(5):757-770. doi: 10.1158/1541-7786.MCR-20-0188. Epub 2021 Jan 25. PMID: 33495401.
Copy Download .nbib Format: NLM
Share it on

Mol Cancer Res. 2021 May;19(5):757-770. doi: 10.1158/1541-7786.MCR-20-0188. Epub 2021 Jan 25.

Adaptor Protein ShcD/.

Molecular cancer research : MCR

Manali Tilak, Begüm Alural, Sarah E Wismer, Megan I Brasher, Laura A New, Steven D Sheridan, Roy H Perlis, Marc G Coppolino, Jasmin Lalonde, Nina Jones

Affiliations

  1. Department of Molecular and Cellular Biology, University of Guelph, Guelph, Ontario, Canada.
  2. Center for Quantitative Health, Center for Genomic Medicine and Department of Psychiatry, Massachusetts General Hospital, Boston, Massachusetts.
  3. Department of Molecular and Cellular Biology, University of Guelph, Guelph, Ontario, Canada. [email protected].

PMID: 33495401 DOI: 10.1158/1541-7786.MCR-20-0188

Abstract

Gliomas are characterized by diffuse infiltration of tumor cells into surrounding brain tissue, and this highly invasive nature contributes to disease recurrence and poor patient outcomes. The molecular mechanisms underlying glioma cell invasion remain incompletely understood, limiting development of new targeted therapies. Here, we have identified phosphotyrosine adaptor protein ShcD as upregulated in malignant glioma and shown that it associates with receptor tyrosine kinase Tie2 to facilitate invasion. In human glioma cells, we find that expression of ShcD and Tie2 increases invasion, and this significant synergistic effect is disrupted with a ShcD mutant that cannot bind Tie2 or hyperphosphorylate the receptor. Expression of ShcD and/or Tie2 further increases invadopodia formation and matrix degradation in U87 glioma cells. In a coculture model, we show that U87-derived tumor spheroids expressing both ShcD and Tie2 display enhanced infiltration into cerebral organoids. Mechanistically, we identify changes in focal adhesion kinase phosphorylation in the presence of ShcD and/or Tie2 in U87 cells upon Tie2 activation. Finally, we identify a strong correlation between transcript levels of ShcD and Tie2 signaling components as well as N-cadherin in advanced gliomas and those with classical or mesenchymal subtypes, and we show that elevated expression of ShcD correlates with a significant reduction in patient survival in higher grade gliomas with mesenchymal signature. Altogether, our data highlight a novel Tie2-ShcD signaling axis in glioma cell invasion, which may be of clinical significance. IMPLICATIONS: ShcD cooperates with Tie2 to promote glioma cell invasion and its elevated expression correlates with poor patient outcome in advanced gliomas.

©2021 American Association for Cancer Research.

References

  1. Chen R, Smith-Cohn M, Cohen AL, Colman H. Glioma subclassifications and their clinical significance. Neurotherapeutics. 2017;14:284–97. - PubMed
  2. Louis DN, Perry A, Reifenberger G, von Deimling A, Figarella-Branger D, Cavenee WK, et al. The 2016 World Health Organization classification of tumors of the central nervous system: a summary. Acta Neuropathol. 2016;131:803–20. - PubMed
  3. Meyer MA. Malignant gliomas in adults. N Engl J Med. 2008;359:1850. - PubMed
  4. Berens ME, Giese A. “… those left behind.” Biology and oncology of invasive glioma cells. Neoplasia. 1999;1:208–19. - PubMed
  5. Eddy RJ, Weidmann MD, Sharma VP, Condeelis JS. Tumor cell invadopodia: invasive protrusions that orchestrate metastasis. Trends Cell Biol. 2017;27:595–607. - PubMed
  6. Mitra SK, Schlaepfer DD. Integrin-regulated FAK-Src signaling in normal and cancer cells. Curr Opin Cell Biol. 2006;18:516–23. - PubMed
  7. Whitehead CA, Nguyen HPT, Morokoff AP, Luwor RB, Paradiso L, Kaye AH, et al. Inhibition of radiation and temozolomide-induced invadopodia activity in glioma cells using FDA-approved drugs. Transl Oncol. 2018;11:1406–18. - PubMed
  8. Wills MKB, Jones N. Teaching an old dogma new tricks: twenty years of Shc adaptor signalling. Biochem J. 2012;447:1–16. - PubMed
  9. Fagiani E, Giardina G, Luzi L, Cesaroni M, Quarto M, Capra M, et al. RaLP, a new member of the Src homology and collagen family, regulates cell migration and tumor growth of metastatic melanomas. Cancer Res. 2007;67:3064–73. - PubMed
  10. Wills MKB, Tong J, Tremblay SL, Moran MF, Jones N. The ShcD signaling adaptor facilitates ligand-independent phosphorylation of the EGF receptor. Mol Biol Cell. 2014;25:739–52. - PubMed
  11. Dumont DJ, Yamaguchi TP, Conlon RA, Rossant J, Breitman ML. Tek, a novel tyrosine kinase gene located on mouse chromosome 4, is expressed in endothelial cells and their presumptive precursors. Oncogene. 1992;7:1471–80. - PubMed
  12. Woo SM, Ho SP, Ki HY, Kyu YJ, Myoung JK, Park H, et al. Expression of angiopoietin 1, 2 and their common receptor Tie2 in human gastric carcinoma: Implication for angiogenesis. J Korean Med Sci. 2006;21:272–8. - PubMed
  13. Peters KG, Coogan A, Berry D, Marks J, Iglehart JD, Kontos CD, et al. Expression of Tie2/Tek in breast tumour vasculature provides a new marker for evaluation of tumour angiogenesis. Br J Cancer. 1998;77:51–6. - PubMed
  14. Zadeh G, Qian B, Okhowat A, Sabha N, Kontos CD, Guha A. Targeting the Tie2/Tek receptor in astrocytomas. Am J Pathol. 2004;164:467–76. - PubMed
  15. Jones N, Master Z, Jones J, Bouchard D, Gunji Y, Sasaki H, et al. Identification of Tek/Tie2 binding partners. Binding to a multifunctional docking site mediates cell survival and migration. J Biol Chem. 1999;274:30896–905. - PubMed
  16. Jones N, Iljin K, Dumont DJ, Alitalo K. Tie receptors: New modulators of angiogenic and lymphangiogenic responses. Nat Rev Mol Cell Biol. 2001;2:257–67. - PubMed
  17. Audero E, Cascone I, Maniero F, Napione L, Arese M, Lanfrancone L, et al. Adaptor ShcA protein binds tyrosine kinase Tie2 receptor and regulates migration and sprouting but not survival of endothelial cells. J Biol Chem. 2004;279:13224–33. - PubMed
  18. Lee OH, Xu J, Fueyo J, Fuller GN, Aldape KD, Alonso MM, et al. Expression of the receptor tyrosine kinase Tie2 in neoplastic glial cells is associated with integrin β1-dependent adhesion to the extracellular matrix. Mol Cancer Res. 2006;4:915–26. - PubMed
  19. Liu D, Martin V, Fueyo J, Lee OH, Xu J, Cortes-Santiago N, et al. Tie2/TEK modulates the interaction of glioma and brain tumor stem cells with endothelial cells and promotes an invasive phenotype. Oncotarget. 2010;1:700–9. - PubMed
  20. Cortes-Santiago N, Hossain MB, Gabrusiewicz K, Fan X, Gumin J, Marini FC, et al. Soluble Tie2 overrides the heightened invasion induced by anti-angiogenesis therapies in gliomas. Oncotarget. 2016;7:16146–57. - PubMed
  21. Jones N, Hardy WR, Friese MB, Jorgensen C, Smith MJ, Woody NM, et al. Analysis of a Shc family adaptor protein, ShcD/Shc4, that associates with muscle-specific kinase. Mol Cell Biol. 2007;27:4759–73. - PubMed
  22. Zimmerman AJ, Hafez AK, Amoah SK, Rodriguez BA, Dell'Orco M, Lozano E, et al. A psychiatric disease-related circular RNA controls synaptic gene expression and cognition. Mol Psychiatry. 2020;25:2712–27. - PubMed
  23. Grossman RL, Heath AP, Ferretti V, Varmus HE, Lowy DR, Kibbe WA, et al. Toward a shared vision for cancer genomic data. N Engl J Med. 2016;375:1109–12. - PubMed
  24. Colaprico A, Silva TC, Olsen C, Garofano L, Cava C, Garolini D, et al. TCGAbiolinks: an R/Bioconductor package for integrative analysis of TCGA data. Nucleic Acids Res. 2016;44:e71. - PubMed
  25. Robinson MD, McCarthy DJ, Smyth GK. edgeR: A Bioconductor package for differential expression analysis of digital gene expression data. Bioinformatics. 2009;26:139–40. - PubMed
  26. Ritchie ME, Phipson B, Wu D, Hu Y, Law CW, Shi W, et al. Limma powers differential expression analyses for RNA-sequencing and microarray studies. Nucleic Acids Res. 2015;43:e47. - PubMed
  27. Zhao Z, Meng F, Wang W, Wang Z, Zhang C, Jiang T. Comprehensive RNA-seq transcriptomic profiling in the malignant progression of gliomas. Sci Data. 2017;4:170024. - PubMed
  28. Kassambara A, Kosinski M, Biecek P. Package “survminer” type package title drawing survival curves using “ggplot2” [Internet]. 2020. - PubMed
  29. Therneau TM, Lumley T. Survival analysis including penalised likelihood [Internet]. 2011. - PubMed
  30. Wei T, Simcoe V. RPackage “corrplot”: Visualization of a correlation matrix (Version 0.84). 2017. - PubMed
  31. Bateman A, Martin MJ, O'Donovan C, Magrane M, Apweiler R, Alpi E, et al. UniProt: a hub for protein information. Nucleic Acids Res. 2015;43:D204–12. - PubMed
  32. Pitre S, Dehne F, Chan A, Cheetham J, Duong A, Emili A, et al. PIPE: A protein-protein interaction prediction engine based on the re-occurring short polypeptide sequences between known interacting protein pairs. BMC Bioinformatics. 2006;7:365. - PubMed
  33. Szklarczyk D, Gable AL, Lyon D, Junge A, Wyder S, Huerta-Cepas J, et al. STRING v11: Protein-protein association networks with increased coverage, supporting functional discovery in genome-wide experimental datasets. Nucleic Acids Res. 2019;47:D607–13. - PubMed
  34. Szklarczyk D, Morris JH, Cook H, Kuhn M, Wyder S, Simonovic M, et al. The STRING database in 2017: quality-controlled protein-protein association networks, made broadly accessible. Nucleic Acids Res. 2017;45:D362–8. - PubMed
  35. Shannon P, Markiel A, Ozier O, Baliga NS, Wang JT, Ramage D, et al. Cytoscape: a software environment for integrated models of biomolecular interaction networks. Genome Res. 2003;13:2498–504. - PubMed
  36. Doncheva NT, Morris JH, Gorodkin J, Jensen LJ. Cytoscape StringApp: network analysis and visualization of proteomics data. J Proteome Res. 2019;18:623–32. - PubMed
  37. Gómez-Rubio V. ggplot2 - Elegant Graphics for Data Analysis (2nd Edition). J Stat Softw. 2017;77:3–5. - PubMed
  38. Kassambara A. ggpubr: “ggplot2” based publication ready plots. R package version 0.4.0. R Package version 018 [Internet]. 2020. - PubMed
  39. Verhaak RGW, Hoadley KA, Purdom E, Wang V, Qi Y, Wilkerson MD, et al. Integrated genomic analysis identifies clinically relevant subtypes of glioblastoma characterized by abnormalities in PDGFRA, IDH1, EGFR, and NF1. Cancer Cell. 2010;17:98–110. - PubMed
  40. Wills MKB, Chahi AK, Lau HR, Tilak M, Guild BD, New LA, et al. Signaling adaptor ShcD suppresses extracellular signal-regulated kinase (Erk) phosphorylation distal to the Ret and Trk neurotrophic receptors. J Biol Chem. 2017;292:5748–59. - PubMed
  41. Sturk C, Kim H, Jones N, Dumont DJ. A negative regulatory role for Y1111 on the Tie-2 RTK. Cell Signal. 2010;22:676–83. - PubMed
  42. Saini P, Courtneidge SA. Tks adaptor proteins at a glance. J Cell Sci. 2018;131:1–6. - PubMed
  43. Ogawa J, Pao GM, Shokhirev MN, Verma IM. Glioblastoma model using human cerebral organoids. Cell Rep. 2018;23:1220–9. - PubMed
  44. Linkous A, Balamatsias D, Snuderl M, Edwards L, Miyaguchi K, Milner T, et al. Modeling patient-derived glioblastoma with cerebral organoids. Cell Rep. 2019;26:3203–11. - PubMed
  45. Jones N, Chen SH, Sturk C, Master Z, Tran J, Kerbel RS, et al. A Unique autophosphorylation site on Tie2/Tek mediates Dok-R phosphotyrosine binding domain binding and function. Mol Cell Biol. 2003;23:2658–68. - PubMed
  46. Songyang Z, Shoelson SE, McGlade J, Olivier P, Pawson T, Bustelo XR, et al. Specific motifs recognized by the SH2 domains of Csk, 3BP2, fps/fes, GRB-2, HCP, SHC, Syk, and Vav. Mol Cell Biol. 1994;14:2777–85. - PubMed
  47. Shewchuk LM, Hassell AM, Ellis B, Holmes WD, Davis R, Horne EL, et al. Structure of the Tie2 RTK domain - Self-inhibition by the nucleotide binding loop, activation loop, and C-terminal tail. Structure. 2000;8:1105–13. - PubMed
  48. New LA, Chahi AK, Jones N. Direct regulation of nephrin tyrosine phosphorylation by Nck adaptor proteins. J Biol Chem. 2013;288:1500–10. - PubMed
  49. Jadwin JA, Curran TG, Lafontaine AT, White FM, Mayer BJ. Src homology 2 domains enhance tyrosine phosphorylation in vivo by protecting binding sites in their target proteins from dephosphorylation. J Biol Chem. 2018;293:623–7. - PubMed
  50. Voskas D, Jones N, Van Slyke P, Sturk C, Chang W, Haninec A, et al. A cyclosporine-sensitive psoriasis-like disease produced in Tie2 transgenic mice. Am J Pathol. 2005;166:843–55. - PubMed
  51. Williams KC, Coppolino MG. SNARE-dependent interaction of Src, EGFR and ß1 integrin regulates invadopodia formation and tumor cell invasion. J Cell Sci. 2014;127:1712–25. - PubMed
  52. Chan KT, Cortesio CL, Huttenlocher A. Fak alters invadopodia and focal adhesion composition and dynamics to regulate breast cancer invasion. J Cell Biol. 2009;185:357–70. - PubMed
  53. Kolli-Bouhafs K, Sick E, Noulet F, Gies JP, De Mey J, Rondé P. FAK competes for Src to promote migration against invasion in melanoma cells. Cell Death Dis. 2014;5:e1379. - PubMed
  54. Lu Z, Jiang G, Blume-Jensen P, Hunter T. Epidermal growth factor-induced tumor cell invasion and metastasis initiated by dephosphorylation and downregulation of focal adhesion kinase. Mol Cell Biol. 2001;21:4016–31. - PubMed
  55. Sturm D, Witt H, Hovestadt V, Khuong-Quang DA, Jones DTW, Konermann C, et al. Hotspot mutations in H3F3A and IDH1 define distinct epigenetic and biological subgroups of glioblastoma. Cancer Cell. 2012;22:425–37. - PubMed
  56. Brennan CW, Verhaak RGW, McKenna A, Campos B, Noushmehr H, Salama SR, et al. The somatic genomic landscape of glioblastoma. Cell. 2013;155:462. - PubMed
  57. Teichert-Kuliszewska K, Maisonpierre PC, Jones N, Campbell AIM, Master Z, Bendeck MP, et al. Biological action of angiopoietin-2 in a fibrin matrix model of angiogenesis is associated with activation of Tie2. Cardiovasc Res. 2001;49:659–70. - PubMed
  58. Daly C, Eichten A, Castanaro C, Pasnikowski E, Adler A, Lalani AS, et al. Angiopoietin-2 functions as a Tie2 agonist in tumor models, where it limits the effects of VEGF inhibition. Cancer Res. 2013;73:108–18. - PubMed
  59. Hu B, Guo P, Fang Q, Tao HQ, Wang D, Nagane M, et al. Angiopoietin-2 induces human glioma invasion through the activation of matrix metalloprotease-2. Proc Natl Acad Sci U S A.. 2003;100:8904–9. - PubMed
  60. Hu B, Jarzynka MJ, Guo P, Imanishi Y, Schlaepfer DD, Cheng SY. Angiopoietin 2 induces glioma cell invasion by stimulating matrix metalloprotease 2 expression through the αvβ1 integrin and focal adhesion kinase signaling pathway. Cancer Res. 2006;66:775–83. - PubMed
  61. De Palma M, Mazzieri R, Politi LS, Pucci F, Zonari E, Sitia G, et al. Tumor-targeted interferon-α Delivery by Tie2-expressing monocytes inhibits tumor growth and metastasis. Cancer Cell. 2008;14:299–311. - PubMed
  62. Gabrusiewicz K, Liu D, Cortes-Santiago N, Hossain MB, Conrad CA, Aldape KD, et al. Anti-vascular endothelial growth factor therapy-induced glioma invasion is associated with accumulation of Tie2-expressing monocytes. Oncotarget. 2014;5:2208–20. - PubMed
  63. Mazzieri R, Pucci F, Moi D, Zonari E, Ranghetti A, Berti A, et al. Targeting the ANG2/TIE2 axis inhibits tumor growth and metastasis by impairing angiogenesis and disabling rebounds of proangiogenic myeloid cells. Cancer Cell. 2011;19:512–26. - PubMed

Publication Types

Grant support